PMID

Data

Article Title

Organization

Structure-activity relationships of phomactin derivatives as platelet activating factor antagonists.

Sankyo

Synthesis of alkyl chain-modified ether lipids and evaluation of their in vitro cytotoxicity.

Laboratorios Menarini

Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.

Pfizer

Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.

Pfizer

3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.

Abbott Laboratories

Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.

Universit£

Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.

American Cyanamid

(Pyridylcyanomethyl)piperazines as orally active PAF antagonists.

J. Uriach & C£A.S.A.

1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.

Pfizer

4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.

Alter

Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.

Takeda Chemical Industries

Structure-activity relationships of kadsurenone analogues.

TBA

 

Synthesis and biological activity of MK 287 (L-680,573): a potent, specific and orally active paf receptor antagonist

TBA

 

Synthesis and evaluation of water soluble indole pyrrolothiazole paf antagonists

TBA

 

Discovery and optimization of indole pyrrolothiazole paf antagonists

TBA

 

The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D₄ (LTD₄)/platelet activating factor (PAF) receptor antagonists.

TBA

 

Synthesis and bioactivities of heterocyclic lipids as PAF antagonists. 2

TBA

 

Synthesis and bioactivities of heterocyclic lipids as PAF antagonists. 1

TBA

 

Synthesis of bicyclic thiazolidine PAF antagonists

TBA

Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.

Columbia University

In vitro platelet-activating factor receptor binding inhibitory activity of pinusolide derivatives: a structure-activity study.

Seoul National University

Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.

Abbott Laboratories

Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.

American Cyanamid

Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.

J. Uriach & CíA.

Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.

Wellcome Research Laboratories

Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists.

TBA

Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.

J. Uriach & CíA.

4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.

J. Uriach & CíA.

Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.

Abbott Laboratories